{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:11:51Z","timestamp":1791231111066,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.thromres.2014.09.006","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T10:33:34Z","timestamp":1410863614000},"page":"1074-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement"],"prefix":"10.1016","volume":"134","author":[{"given":"B\u00e9rang\u00e8re","family":"Joly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Stepanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hajage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Thouzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Capdenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.09.006_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.09.006_bb0010","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.09.006_bb0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2014.09.006_bb0020","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.09.006_bb0025","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.09.006_bb0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.09.006_bb0035","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.09.006_bb0040","first-page":"1029","article-title":"Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome","volume":"88","author":"Lattuada","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.09.006_bb0045","doi-asserted-by":"crossref","first-page":"204-10","DOI":"10.1182\/blood-2014-01-550244","article-title":"French Thrombotic Micronagiopathies Reference center. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.09.006_bb0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1538-7836.2010.03761.x","article-title":"ADAMTS-13 assays in thrombotic thrombocytopenic purpura","volume":"8","author":"Peyvandi","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0055","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1538-7836.2003.00385.x","article-title":"Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods","volume":"1","author":"Studt","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0060","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1538-7836.2004.00879.x","article-title":"Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas","volume":"2","author":"Tripodi","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0065","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1160\/TH06-03-0166","article-title":"Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples","volume":"95","author":"Mahdian","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.09.006_bb0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jth.12221","article-title":"Structure-function and regulation of ADAMTS-13 protease","volume":"11","author":"Zheng","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0080","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/jth.12319","article-title":"An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura","volume":"11","author":"Muia","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0085","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/asheducation-2013.1.292","article-title":"Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies","volume":"2013","author":"Crawley","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Suppl. 3","key":"10.1016\/j.thromres.2014.09.006_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2516.1998.0040s3015.x","article-title":"The determination of von Willebrand factor activity by collagen binding assay","volume":"4","author":"Siekmann","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2014.09.006_bb0095","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1055\/s-0037-1614780","article-title":"Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP)","volume":"82","author":"Gerritsen","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0100","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1160\/TH12-08-0565","article-title":"Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies","volume":"109","author":"Mackie","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0105","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1160\/TH13-05-0393","article-title":"Evaluation of a commercial assay for ADAMTS13 activity measurement","volume":"110","author":"Thouzeau","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.09.006_bb0110","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.09.006_bb0115","first-page":"112","article-title":"FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients","author":"Mancini","year":"2014","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814004885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814004885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T21:53:00Z","timestamp":1565819580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814004885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0049384814004885"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.09.006","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}